Nom du produit:ethyl 2-(2-methyl-4-sulfanylphenoxy)acetate
IUPAC Name:ethyl 2-(2-methyl-4-sulfanylphenoxy)acetate
- CAS：343322-82-7
- Formule moléculaire：C11H14O3S
- Pureté：95%+
- Numéro de catalogue：CM1075083
- Poids moléculaire：226.29
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:343322-82-7
- Formule moléculaire:C11H14O3S
- Point de fusion:-
- Code SMILES:CCOC(=O)COC1=CC=C(S)C=C1C
- Densité:
- Numéro de catalogue:CM1075083
- Poids moléculaire:226.29
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Seladelpar
- Recently, CymaBay Therapeutics announced it has submitted a New Drug Application (NDA) to the FDA for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid (UDCA). CymaBay has requested a Priority Review of the NDA that, if accepted, would mean the FDA would plan to complete its review within six months of accepting the application. Seladelpar has been granted Breakthrough Therapy Designation by the FDA and is the only potent, selective, orally active delpar, or PPARδ agonist, with Phase 3 trial results demonstrating a statistically significant improvement in markers of cholestasis related to risk of progression and PBC-related pruritus.
Recherche 
+86 21 5895 0110 
